Vivo Capital LLC Boosts Stock Holdings in Trevi Therapeutics, Inc. $TRVI

Vivo Capital LLC lifted its stake in shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI) by 28.7% in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 4,487,903 shares of the company’s stock after acquiring an additional 1,000,000 shares during the quarter. Trevi Therapeutics comprises approximately 2.5% of Vivo Capital LLC’s holdings, making the stock its 8th largest position. Vivo Capital LLC’s holdings in Trevi Therapeutics were worth $24,549,000 as of its most recent SEC filing.

A number of other hedge funds have also made changes to their positions in the stock. Vanguard Group Inc. grew its holdings in Trevi Therapeutics by 9.4% during the first quarter. Vanguard Group Inc. now owns 3,838,032 shares of the company’s stock valued at $24,141,000 after purchasing an additional 328,819 shares during the last quarter. MPM Bioimpact LLC lifted its stake in shares of Trevi Therapeutics by 10.8% in the first quarter. MPM Bioimpact LLC now owns 3,428,366 shares of the company’s stock worth $21,564,000 after buying an additional 333,470 shares during the last quarter. Octagon Capital Advisors LP bought a new stake in shares of Trevi Therapeutics during the 1st quarter worth $20,895,000. Armistice Capital LLC acquired a new position in Trevi Therapeutics in the 1st quarter valued at $18,795,000. Finally, Affinity Asset Advisors LLC lifted its position in Trevi Therapeutics by 102.7% during the 2nd quarter. Affinity Asset Advisors LLC now owns 2,534,058 shares of the company’s stock worth $13,861,000 after acquiring an additional 1,284,058 shares during the last quarter. Institutional investors and hedge funds own 95.76% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on TRVI. D. Boral Capital reaffirmed a “buy” rating and issued a $19.00 price target on shares of Trevi Therapeutics in a research report on Friday, November 14th. Morgan Stanley increased their target price on Trevi Therapeutics from $18.00 to $19.00 and gave the company an “overweight” rating in a research note on Friday, November 14th. Leerink Partners lifted their price target on Trevi Therapeutics from $13.00 to $16.00 and gave the stock an “outperform” rating in a research report on Wednesday, November 19th. Oppenheimer increased their price objective on Trevi Therapeutics from $23.00 to $24.00 and gave the company an “outperform” rating in a research report on Friday, November 14th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Trevi Therapeutics in a research report on Wednesday, October 8th. Two analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Trevi Therapeutics presently has an average rating of “Buy” and an average price target of $21.44.

Trevi Therapeutics Stock Performance

Shares of Trevi Therapeutics stock opened at $12.98 on Tuesday. The firm has a market cap of $1.66 billion, a P/E ratio of -35.08 and a beta of 0.82. The firm’s 50-day simple moving average is $11.15 and its 200-day simple moving average is $8.50. Trevi Therapeutics, Inc. has a twelve month low of $2.36 and a twelve month high of $14.00.

Trevi Therapeutics (NASDAQ:TRVI) last announced its quarterly earnings results on Thursday, November 13th. The company reported ($0.08) EPS for the quarter, topping analysts’ consensus estimates of ($0.10) by $0.02. On average, equities analysts forecast that Trevi Therapeutics, Inc. will post -0.49 earnings per share for the current fiscal year.

Trevi Therapeutics Company Profile

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.